1.Medical treatment of rheumatoid arthritis.
Korean Journal of Medicine 1999;57(3):387-389
No abstract available.
Arthritis, Rheumatoid*
2.Novel treatment of rheumatoid arthritis.
Journal of the Korean Academy of Family Medicine 2001;22(1):21-28
No abstract available.
Arthritis, Rheumatoid*
3.Oral Tolerance Therapy in Rheumatoid Arthritis.
The Journal of the Korean Rheumatism Association 2000;7(1):1-12
No abstract available.
Arthritis, Rheumatoid*
4.Osteoclastogenesis in Rheumatoid Arthritis.
Journal of Rheumatic Diseases 2011;18(2):71-73
No abstract available.
Arthritis, Rheumatoid
5.Anti-TNF-alpha Therapy for Rheumatoid Arthritis.
The Journal of the Korean Rheumatism Association 2000;7(2):105-111
No abstract available.
Arthritis, Rheumatoid*
6.Evaluation of disease activity in rheumatoid arthritis.
Korean Journal of Medicine 1999;57(5):965-966
No abstract available.
Arthritis, Rheumatoid*
7.Evaluation of disease activity in rheumatoid arthritis.
Korean Journal of Medicine 1999;57(5):965-966
No abstract available.
Arthritis, Rheumatoid*
8.Pathogenesis of rheumatoid arthritis.
The Journal of the Korean Rheumatism Association 1994;1(1):1-12
No abstract available.
Arthritis, Rheumatoid*
9.Update on rheumatoid arthritis.
Korean Journal of Medicine 2009;76(3):296-299
No abstract available.
Arthritis, Rheumatoid
10.Methotrexate toxicity and associated risk factors in Filipino patients with Rheumatoid Arthritis included in the Rheumatoid Arthritis Database and Registry
Eliza Mia M. Dejoras ; Jakes Catherine M. Panggat ; Angeline-Therese M. Santiago ; Ester G. Penserga
Philippine Journal of Internal Medicine 2018;56(4):210-214
Introduction:
Rheumatoid arthritis (RA) is a chronic autoimmune disease that is severely debilitating with a prevalence in the Philippines of 0.17-0.4%. This study aims to determine rate of methotrexate (MTX) toxicity, identify risk factors and comorbid conditions predisposing to toxicity and describe management of MTX toxicity.
Methods:
Rheumatoid arthritis (RA) cases from the Rheumatoid Arthritis Database and Registry (RADAR) diagnosed by the 1987 ACR criteria receiving MTX monotherapy or combination disease modifying anti-rheumatic drugs (DMARDs), with at least one dose of treatment, were included. Patients were grouped into those with and without adverse events (AE). Disease activity was measured using DAS 28-ESR. Baseline characteristics, duration of use, dose, concomitant drugs and all toxicities were listed. Management of AEs were described. Independent t-test and Mann-Whitney U test were used for numerical data and Chi-square and Fisher’s exact test for continuous data.
Results:
One hundred ninety four patients are included, with 95% females, age 35-64 years, disease duration of 0.2-10 years. Eighty three percent are on methotrexate monotherapy. Fifty cases (25.77%) all with dose of 8.75±2.5 had AEs: hepatotoxicity (52%), gastrointestinal (24%), hematologic (14%), dermatologic (8%), pulmonary (6%). Risk factors directly correlated with toxicity were older age (p=0.024), disease duration (p=0.024 ), dose (p<0.000), duration of use (p≤0.001), anemia (p=0.038) and osteoarthritis (p=0.011).Management included dose reduction (52%), dose retention with close monitoring (26%), addition of (24%) or shift to (22%) other DMARDS. Folate dose was increased in all cases.
Conclusion
Methotrexate (MTX) toxicity rate of RA patients from the RADAR is similar to those in literature. While dose reduction is the main management strategy, some patients’ doses were maintained while others were shifted to other DMARDS.
Arthritis, Rheumatoid
Result Analysis
Print
Save
E-mail